Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. Allegations - The lawsuit claims that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness, overstating its clinical, regulatory, and commercial prospects [2]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than represented, leading to an overestimation of Alto's business and financial prospects [2]. Stock Performance - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4].

Core Viewpoint - NorthWestern (NWE) reported quarterly earnings of $0.4 per share, exceeding the Zacks Consensus Estimate of $0.38 per share, but down from $0.53 per share a year ago, indicating a mixed performance in earnings [1][2] Financial Performance - The company achieved revenues of $342.7 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.72% and showing an increase from $319.9 million year-over-year [2] - Over the last four quarters, NorthWestern has exceeded consensus EPS estimates two times and topped revenue estimates three times [2] Stock Performance - NorthWestern shares have declined approximately 1.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.81 on revenues of $377.21 million, and for the current fiscal year, it is $3.60 on revenues of $1.59 billion [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which may influence future stock performance [6] Industry Context - The Utility - Electric Power industry, to which NorthWestern belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Carvana said Wednesday (July 30) that it achieved record retail unit sales and revenue in the second quarter as it continued to refine its online automotive retail business.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins re ...

With over $40 million in expected cash on hand, Duos is now fully capitalized to fulfill its $50 million revenue pipeline and advance deployment of an additional 65 Edge Data Centers Offering included primary participation from fundamental institutional investors, including a leading long-only mutual fund, several preeminent global investment managers, and existing investors JACKSONVILLE, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT) a provide ...

Lam Research Corporation (NASDAQ: LRCX ) is a semiconductor company that provides equipment to manufacturers in order to help them produce chips. The company's equipment is highly sophisticated and highly advanced. These equipment is typically used in wafer construction etching, deposition, and cleaningI own separate portfolios for separate goals. I have one portfolio where I have nothing but income plays, another portfolio where I have nothing but growth stocks. I also have another portfolio where I run my ...

Core Insights - MGM Resorts reported $4.4 billion in revenue for Q2 2025, a year-over-year increase of 1.8% and a surprise of +2.42% over the Zacks Consensus Estimate of $4.3 billion [1] - The EPS for the same period was $0.79, down from $0.86 a year ago, with an EPS surprise of +36.21% compared to the consensus estimate of $0.58 [1] Financial Performance Metrics - MGM's shares returned +1.4% over the past month, while the Zacks S&P 500 composite increased by +3.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3] Las Vegas Strip Resorts Performance - Table Games Drop: $1,554.00 vs. $1,506.00 estimated [4] - Slots Win: $549.00 vs. $539.99 estimated [4] - Slots Handle: $5,886.00 vs. $5,775.24 estimated [4] - Table Games Win: $355.00 vs. $401.08 estimated [4] - Revenues for Las Vegas Strip Resorts: $2.11 billion vs. $2.15 billion estimated, representing a -4.1% change year-over-year [4] Regional Operations and MGM China - Revenues for Regional Operations: $964.61 million vs. $940.66 million estimated, a +4% year-over-year change [4] - Revenues for MGM China: $1.11 billion vs. $1.03 billion estimated, a +24.6% year-over-year change [4] Digital and Other Operations - Revenues for MGM Digital: $163.86 million vs. $172.4 million estimated [4] - Revenues for Management and Other Operations: $51.61 million vs. $173.2 million estimated, a -70.8% year-over-year change [4] Adjusted Property EBITDA - Adjusted Property EBITDA for Las Vegas Strip Resorts: $710.5 million vs. $740.76 million estimated [4] - Adjusted Property EBITDA for Regional Operations: $308.66 million vs. $288.97 million estimated [4] - Adjusted Property EBITDA for MGM China: $301.34 million vs. $270.26 million estimated [4]

For the quarter ended June 2025, Methanex (MEOH) reported revenue of $797 million, down 13.4% over the same period last year. EPS came in at $0.97, compared to $0.62 in the year-ago quarter.The reported revenue represents a surprise of -8.8% over the Zacks Consensus Estimate of $873.92 million. With the consensus EPS estimate being $0.42, the EPS surprise was +130.95%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Prudential (PRU) reported $13.51 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 2.4%. EPS of $3.58 for the same period compares to $3.39 a year ago.The reported revenue represents a surprise of +0.2% over the Zacks Consensus Estimate of $13.48 billion. With the consensus EPS estimate being $3.21, the EPS surprise was +11.53%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine thei ...

Core Insights - Murphy USA reported $5.01 billion in revenue for the quarter ended June 2025, reflecting an 8.2% year-over-year decline, while EPS increased to $7.36 from $6.92 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $5.47 billion, resulting in a surprise of -8.55%, whereas the EPS exceeded the consensus estimate of $6.82 by 7.92% [1] Revenue Breakdown - Petroleum product sales generated $3.85 billion, which is 11.3% lower year-over-year and below the average estimate of $4.23 billion [4] - Other operating revenues reached $61.2 million, significantly exceeding the average estimate of $45.95 million, marking a 98.7% year-over-year increase [4] - Merchandise sales totaled $1.09 billion, slightly below the average estimate of $1.11 billion, with a year-over-year increase of 1.1% [4] Stock Performance - Over the past month, Murphy USA's shares have returned -1.5%, contrasting with the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Ambiq Micro, a 15-year-old manufacturer of energy-efficient chips for wearable and medical devices, closed its first day of trading on Wednesday at $38.53 a share, a 61% increase from the $24 IPO price the company set the previous day.The success of the IPO signals strong investor demand in the public market for new small-cap companies benefiting from AI innovation. Ambiq closed its first day as a public company with a valuation of $656 million (excluding employee options). This represents a significant in ...